Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 171
Filtrer
1.
Nat Commun ; 14(1): 7290, 2023 Nov 10.
Article de Anglais | MEDLINE | ID: mdl-37949854

RÉSUMÉ

Increasing the carrier density in a Mott insulator by chemical doping gives rise to a generic superconducting dome in high temperature superconductors. An intriguing question is whether a second superconducting dome may exist at higher dopings. Here we heavily overdope La2-xSrxCuO4 (0.45 ≤ x ≤ 1.0) and discover an unprecedented reentrance of interface superconductivity in La2-xSrxCuO4 /La2CuO4 heterostructures. As x increases, the superconductivity is weakened and completely fades away at x = 0.8; but it revives at higher doping and fully recovers at x = 1.0. This is shown to be correlated with the suppression of the interfacial charge transfer around x = 0.8 and the weak-to-strong localization crossover in the La2-xSrxCuO4 layer. We further construct a theoretical model to account for the sophisticated relation between charge localization and interfacial charge transfer. Our work advances both the search for and control of new superconducting heterostructures.

2.
Nat Commun ; 14(1): 7046, 2023 Nov 10.
Article de Anglais | MEDLINE | ID: mdl-37949859

RÉSUMÉ

Large laser facilities have recently enabled material characterization at the pressures of Earth and Super-Earth cores. However, the temperature of the compressed materials has been largely unknown, or solely relied on models and simulations, due to lack of diagnostics under these challenging conditions. Here, we report on temperature, density, pressure, and local structure of copper determined from extended x-ray absorption fine structure and velocimetry up to 1 Terapascal. These results nearly double the highest pressure at which extended x-ray absorption fine structure has been reported in any material. In this work, the copper temperature is unexpectedly found to be much higher than predicted when adjacent to diamond layer(s), demonstrating the important influence of the sample environment on the thermal state of materials; this effect may introduce additional temperature uncertainties in some previous experiments using diamond and provides new guidance for future experimental design.

3.
Zhonghua Er Ke Za Zhi ; 60(11): 1172-1177, 2022 Nov 02.
Article de Chinois | MEDLINE | ID: mdl-36319153

RÉSUMÉ

Objective: To evaluate the efficacy of the Hodgkin lymphoma (HL)-2013 regimen in the treatment of children with HL, and to investigate the prognostic factors of childhood HL. Methods: Clinical data of 145 children (aged ≤18 years) with newly diagnosed HL, treated with HL-2013 regimen in 8 tertiary referral centers for childhood cancer from August 2011 to April 2021 were analyzed retrospectively. All the diagnosis were confirmed by histopathological morphology and immunohistochemical examination. The clinical characteristics and treatment outcomes were summarized, and the patients were divided into different groups according to clinical characteristics. Kaplan-Meier method was used for survival analysis, and the comparison of survival rates between groups was performed with Log-rank test. Results: Of the 145 cases, there were 115 males and 30 females, the age at diagnosis was 7.9 (5.8, 10.6) years. Cervical lymph node enlargement (114 cases, 78.6%) was the common symptom of the disease, and 57 patients (39.3%) were accompanied by large masses. The most common pathological classification was mixed cell type (93 cases, 64.1%). According to the Ann Arbor staging system, there were 9 cases of stage Ⅰ, 62 cases of stage Ⅱ, 45 cases of stage Ⅲ, 29 cases of stage Ⅳ. According to the risk stratification: there were 14 cases of low-risk group, 76 cases of medium-risk group and 55 cases of high-risk group. Of all patients, 68 cases (46.9%) achieved an early complete remission (CR) after 2 courses of chemotherapy, and the CR rate was 93.8% (136/145) after first-line treatment. Disease recurrence or progression occurred in 22 cases (15.2%). Of all patients, 125 cases survived, 6 cases died and 14 cases were lost to follow-up. Among the survived cases, 123 cases were continuously at CR state,and the follow-up time was 55 (40, 76) months. The 5-year overall survival (OS) and event free survival (EFS) rates were (95.3±1.9)% and (84.2±3.0)% for the entire group, respectively. 5-year OS and EFS rates for patients with stage Ⅲ-Ⅳ were both lower than those for patients with stage Ⅰ-Ⅱ (χ2=6.28 and 7.58, both P<0.05), the 5-year OS and EFS rates for patients in high-risk group were both lower than those for patients in low-risk and medium-risk group (χ2=10.93, 7.79, both P<0.05). The 5-year OS rates for the patient with early CR and without early CR were 100.0% and (90.9±3.6)% (χ2=5.77, P=0.016). EFS rates for the patient with early CR (68 cases) and without early CR (77 cases) were (93.8±3.0)% and (75.8±5.0)% (χ2=8.78, P=0.003). Conclusions: HL-2013 regimen is significantly effective in the treatment of pediatric HL. However, the patients in high-risk group and those without early CR are prone to disease recurrence or progression. Stage Ⅲ-Ⅳ and without early CR were associated with worse prognosis.


Sujet(s)
Maladie de Hodgkin , Enfant , Femelle , Mâle , Humains , Études rétrospectives , Récidive tumorale locale , Chine , Protocoles de polychimiothérapie antinéoplasique , Pronostic , Survie sans rechute
4.
Eur Rev Med Pharmacol Sci ; 26(24): 9212-9220, 2022 12.
Article de Anglais | MEDLINE | ID: mdl-36591833

RÉSUMÉ

OBJECTIVE: To observe the clinical effect of a combination of traditional Chinese and western medicine (sacral canal therapy combined with compound Fufang Wulingzhi Tangjiang) in the treatment of residual root pain after lumbar surgery. PATIENTS AND METHODS: From January 2019 to December 2020, 538 patients with residual root pain due to lumbar degenerative diseases were treated in our hospital [open decompression discectomy (ODD), Percutaneous Endoscopic Lumbar Discectomy (PELD) or Transforminal Lumbar Interbody Fusion (TLIF)]. They were randomly divided into control group (basic treatment + celecoxib), observation group 1 (basic treatment + compound Fufang Wulingzhi Tangjiang), observation group 2 (basic treatment + sacral canal therapy) and observation group 3 (basic treatment + sacral canal therapy + Fufang Wulingzhi Tangjiang). Follow-up 3-12 months. The therapeutic effect, VAS score, JOA score, treatment cost, complications, serum interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-α) were recorded and compared before treatment, 1 week after treatment, 2 weeks after treatment, 1 month after treatment, and the last follow-up. RESULTS: The treatment effect, VAS score, JOA, and treatment cost in the observation group were better than those in the control group (p < 0.05). There were significant differences in the above-mentioned indexes between the observation group 3 and the control group, observation group 1, and observation group 2 (p < 0 01). Inflammatory factors (IL-6, IL1, TNF-α) in the observation group were lower than those in the control group (p < 0 05). Inflammatory factors in observation group 3 were significantly lower than those in the control group, observation group 1, and observation group 2 (p < 0 01). CONCLUSIONS: Sacral canal injection combined with Fufang Wulingzhi Tangjiang can be effective in the treatment of postoperative root pain of lumbar degenerative diseases, which can reduce inflammatory factors such as IL-6, IL-1ß and TNF-α. It has the advantages of quick effect, short treatment time, low cost, high safety, in line with the concept of ERAS, easily accepted by patients and their families, and worthy of further popularizing and applying in clinic.


Sujet(s)
Discectomie percutanée , Déplacement de disque intervertébral , Arthrodèse vertébrale , Humains , Interleukine-6 , Déplacement de disque intervertébral/chirurgie , Vertèbres lombales/chirurgie , Douleur , Études rétrospectives , Résultat thérapeutique , Facteur de nécrose tumorale alpha
5.
Nat Commun ; 12(1): 4495, 2021 07 23.
Article de Anglais | MEDLINE | ID: mdl-34301946

RÉSUMÉ

Zoonotic transfer of animal pathogens to human hosts can generate novel agents, but the genetic events following such host jumps are not well studied. Here we characterize the mechanisms driving adaptive evolution of the emerging zoonotic pathogen Bordetella hinzii in a patient with interleukin-12 receptor ß1 deficiency. Genomic sequencing of 24 B. hinzii isolates cultured from blood and stool over 45 months revealed a clonal lineage that had undergone extensive within-host genetic and phenotypic diversification. Twenty of 24 isolates shared an E9G substitution in the DNA polymerase III ε-subunit active site, resulting in a proofreading deficiency. Within this proofreading-deficient clade, multiple lineages with mutations in DNA repair genes and altered mutational spectra emerged and dominated clinical cultures for more than 12 months. Multiple enzymes of the tricarboxylic acid cycle and gluconeogenesis pathways were repeatedly mutated, suggesting rapid metabolic adaptation to the human environment. Furthermore, an excess of G:C > T:A transversions suggested that oxidative stress shaped genetic diversification during adaptation. We propose that inactivation of DNA proofreading activity in combination with prolonged, but sub-lethal, oxidative attack resulting from the underlying host immunodeficiency facilitated rapid genomic adaptation. These findings suggest a fundamental role for host immune phenotype in shaping pathogen evolution following zoonotic infection.


Sujet(s)
Adaptation physiologique/génétique , Bordetella/génétique , Évolution moléculaire , Sujet immunodéprimé/génétique , Animaux , Protéines bactériennes/génétique , Zoonoses bactériennes/microbiologie , Bordetella/classification , Bordetella/physiologie , DNA polymerase III/génétique , Interactions hôte-pathogène/génétique , Humains , Mutation , Phylogenèse , Volaille/microbiologie , Récepteurs à l'interleukine-12/déficit , Récepteurs à l'interleukine-12/génétique
6.
J Endocrinol Invest ; 44(11): 2375-2386, 2021 Nov.
Article de Anglais | MEDLINE | ID: mdl-33646556

RÉSUMÉ

BACKGROUND: This study aimed to identify the potential circulating biomarkers of protein, mRNAs, and long non-coding RNAs (lncRNAs) to differentiate the papillary thyroid cancers from benign thyroid tumors. METHODS: The study population of 100 patients was classified into identification (10 patients with papillary thyroid cancers and 10 patients with benign thyroid tumors) and validation groups (45 patients with papillary thyroid cancers and 35 patients with benign thyroid tumors). The Sengenics Immunome Protein Array-combined data mining approach using the Open Targets Platform was used to identify the putative protein biomarkers, and their expression validated using the enzyme-linked immunosorbent assay. Next-generation sequencing by Illumina HiSeq was used for the detection of dysregulated mRNAs and lncRNAs. The website Timer v2.0 helped identify the putative mRNA biomarkers, which were significantly over-expressed in papillary thyroid cancers than in adjacent normal thyroid tissue. The mRNA and lncRNA biomarker expression was validated by a real-time polymerase chain reaction. RESULTS: Although putative protein and mRNA biomarkers have been identified, their serum expression could not be confirmed in the validation cohorts. In addition, seven lncRNAs (TCONS_00516490, TCONS_00336559, TCONS_00311568, TCONS_00321917, TCONS_00336522, TCONS_00282483, and TCONS_00494326) were identified and validated as significantly downregulated in patients with papillary thyroid cancers compared to those with benign thyroid tumors. These seven lncRNAs showed moderate accuracy based on the area under the curve (AUC = 0.736) of receiver operating characteristic in predicting the occurrence of papillary thyroid cancers. CONCLUSIONS: We identified seven downregulated circulating lncRNAs with the potential for predicting the occurrence of papillary thyroid cancers.


Sujet(s)
Protéines tumorales , Tumeurs , ARN long non codant/sang , Cancer papillaire de la thyroïde , Tumeurs de la thyroïde , Aire sous la courbe , Marqueurs biologiques tumoraux/sang , Marqueurs biologiques tumoraux/classification , Acides nucléiques acellulaires/sang , Diagnostic différentiel , Régulation négative , Femelle , Analyse de profil d'expression de gènes/méthodes , Régulation de l'expression des gènes tumoraux , Séquençage nucléotidique à haut débit/méthodes , Humains , Mâle , Adulte d'âge moyen , Protéines tumorales/sang , Protéines tumorales/classification , Tumeurs/sang , Tumeurs/diagnostic , Valeur prédictive des tests , Cancer papillaire de la thyroïde/sang , Cancer papillaire de la thyroïde/diagnostic , Tumeurs de la thyroïde/sang , Tumeurs de la thyroïde/diagnostic
7.
Eur Rev Med Pharmacol Sci ; 24(2): 851-861, 2020 01.
Article de Anglais | MEDLINE | ID: mdl-32016991

RÉSUMÉ

OBJECTIVE: Sepsis is a systemic inflammatory response that can lead to the dysfunction of many organs, including the cardiac one. Long noncoding RNAs (lncRNAs) have been shown to be involved in multiple organ injuries induced by sepsis. However, the regulatory effect of nuclear enriched abundant transcript 1 (NEAT1) on sepsis-induced myocardial injury remains to be explored. MATERIALS AND METHODS: The sepsis models of myocardial cell injury were constructed using lipopolysaccharide (LPS). Cell counting kit-8 (CCK-8) assay was used to detect cell viability. Flow cytometry was performed to assess cell apoptosis. Moreover, the levels of apoptosis-related and nuclear factor-kappa B (NF-κB) signaling pathway-related proteins were evaluated by Western blot (WB) analysis. Besides, the contents of inflammatory cytokines were tested by enzyme-linked immunosorbent assay (ELISA). The expression levels of NEAT1 and microRNA-144-3p (miR-144-3p) were determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). In addition, Dual-Luciferase reporter and RNA immunoprecipitation (RIP) assays were used to verify the interaction between NEAT1 and miR-144-3p. RESULTS: LPS could induce myocardial cell injury to construct sepsis models. NEAT1 was upregulated in LPS-treated myocardial cells, and its knockdown promoted viability, suppressed apoptosis, and relieved inflammatory response in LPS-induced myocardial cell injury. MiR-144-3p was downregulated in LPS-treated myocardial cells, and the effect of its overexpression on LPS-induced myocardial cell injury was similar to the effect of NEAT1 knockdown. Besides, miR-144-3p could be sponged by NEAT1, and its inhibitor could reverse the effect of NEAT1 knockdown on LPS-induced myocardial cell injury. Moreover, NEAT1 and miR-144-3p could regulate the activity of NF-κB signaling pathway. CONCLUSIONS: LncRNA NEAT1 could interact with miR-144-3p to regulate sepsis-induced myocardial cell injury through the NF-κB signaling pathway, which might provide a new theoretical basis for the study on the effect of sepsis treatment.


Sujet(s)
microARN/métabolisme , Myocytes cardiaques/métabolisme , ARN long non codant/métabolisme , Sepsie/métabolisme , Animaux , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/physiologie , Relation dose-effet des médicaments , Lipopolysaccharides/toxicité , Souris , Myocytes cardiaques/effets des médicaments et des substances chimiques , Myocytes cardiaques/anatomopathologie , Sepsie/induit chimiquement , Sepsie/anatomopathologie
8.
J Appl Microbiol ; 128(6): 1624-1633, 2020 Jun.
Article de Anglais | MEDLINE | ID: mdl-31951091

RÉSUMÉ

AIMS: To study the association between number and positions of mutations with MICs of fluoroquinolone non-susceptible Haemophilus influenzae. METHODS AND RESULTS: More than 40% of 48 H. influenzae isolated from nursing home residents were not susceptible to fluoroquinolone. Amino acid changes in the quinolone resistance determining regions, and correlation with MICs and inhibition zone diameters were analysed. All isolates with reduced susceptibility to fluoroquinolones (MIC ≥0·125 µg ml-1 ) had at least one mutation in gyrA at position 84 and were resistant to nalidixic acid. Compared to isolates with reduced susceptibility, resistant isolates were associated with mutations in gyrA at positions 88 and 134, and in parC at position 88 (P < 0·001). Inhibition zone diameter for nalidixic acid disk ≥23 mm may detect susceptible isolates. CONCLUSIONS: Reduced susceptibility to fluoroquinolones was associated with mutations at position 84 in gyrA. A further increase in fluoroquinolone MIC was associated with mutations in gyrA at positions 88 and 134, and parC at position 88. SIGNIFICANCE AND IMPACT OF THE STUDY: Due to limited resistant H. influenzae strains, prior studies on association between positions of mutations and fluoroquinolone MICs were inconclusive. The comparison of mutations between isolates with susceptibility, reduced susceptibility and high resistance supported the importance of the present study.


Sujet(s)
Anti-infectieux/pharmacologie , Résistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Résistance bactérienne aux médicaments/génétique , Fluoroquinolones/pharmacologie , Haemophilus influenzae/effets des médicaments et des substances chimiques , DNA gyrase/génétique , DNA topoisomerase IV/génétique , Infections à Haemophilus/microbiologie , Haemophilus influenzae/génétique , Haemophilus influenzae/isolement et purification , Humains , Tests de sensibilité microbienne , Mutation , Maisons de repos , Taïwan
9.
Zhonghua Jie He He Hu Xi Za Zhi ; 41(3): 220-224, 2018 Mar 12.
Article de Chinois | MEDLINE | ID: mdl-29518852
10.
Neoplasma ; 65(1): 161-166, 2018.
Article de Anglais | MEDLINE | ID: mdl-29017331

RÉSUMÉ

Lung cancer is the leading cause of cancer morbidity and mortality around world. Heat shock protein beta-1 (HSPB1) expression is aberrantly increased in non-small cell lung cancer (NSCLC) patients. However, the roles of HSPB1 expression in the prognosis of NSCLC are still elusive. In this study, we investigated the prognostic roles of HSPB1 in NSCLC by using "The Kaplan-Meier plotter" (KM plotter) database. Our data indicated that HSPB1 mRNA low expression was correlated to better overall survival (OS) for all NSCLC patients, hazard ratio (HR) 1.41 (1.24-1.61), p=1.1e-7, and better OS in lung adenocarcinoma (LUAD) patients, HR 1.81 (1.42-2.32), p=1.5e-06, but not in lung squamous cell carcinoma (LUSC) patients, HR 1.21 (0.94-1.55), p=0.14. In addition, mRNA low expression of HSPB1 is also significantly associated with better OS of NSCLC patients in different smoking status, in different chemotherapy status, in clinical stage I et II, as well as patients with successful surgery treatment. Our results indicated that HSPB1 expression may have distinct prognostic values in NSCLC patients, and may provide an effective clinical strategy to accurately predict the prognosis of NSCLC patients.


Sujet(s)
Carcinome pulmonaire non à petites cellules/diagnostic , Protéines du choc thermique HSP27/génétique , Tumeurs du poumon/diagnostic , Carcinome pulmonaire non à petites cellules/génétique , Protéines du choc thermique , Humains , Tumeurs du poumon/génétique , Chaperons moléculaires , Pronostic
11.
Colloids Surf B Biointerfaces ; 158: 147-156, 2017 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-28688364

RÉSUMÉ

Microarc oxidation (MAO) coated magnesium (Mg) with improved corrosion resistance appeal increasing interests as a revolutionary biodegradable metal for fractured bone fixing implants application. However, the in vivo corrosion degradation of the implants and bone healing response are not well understood, which is highly required in clinic. In the present work, 10µm and 20µm thick biocompatible MAO coatings mainly composed of MgO, Mg2SiO4, CaSiO3 and Mg3(PO4)2 phases were fabricated on AZ31 magnesium alloy. The electrochemical tests indicated an improved corrosion resistance of magnesium by the MAO coatings. The 10µm and 20µm coated and uncoated magnesium plates were separately implanted into the radius bone fracture site of adult New Zealand white rabbits using a 3mm width bone fracture defect model to investigate the magnesium implants degradation and uninhibited bone healing. Taking advantage of the good biocompatibility of the MAO coatings, no adverse effects were detected through the blood test and histological examination. The implantation groups of coated and uncoated magnesium plates were both observed the promoting effect of bone fracture healing compared with the simple fracture group without implant. The releasing Mg2+ by the degradation of implants into the fracture site improved the bone fracture healing, which is attributed to the magnesium promoting CGRP-mediated osteogenic differentiation. Mg degradation and bone fracture healing promoting must be tailored by microarc oxidation coating with different thickness for potential clinic application.


Sujet(s)
Matériaux revêtus, biocompatibles/composition chimique , Fractures osseuses/traitement médicamenteux , Magnésium/composition chimique , Animaux , Différenciation cellulaire/effets des médicaments et des substances chimiques , Consolidation de fracture/effets des médicaments et des substances chimiques , Oxydoréduction , Lapins
13.
15.
Zhonghua Zhong Liu Za Zhi ; 38(9): 693-7, 2016 Sep 23.
Article de Chinois | MEDLINE | ID: mdl-27647403

RÉSUMÉ

OBJECTIVE: To study the clinical significance and prognostic value of combined detection of urinary N-terminal telopeptide of type Ⅰ collagen (NTx) and serum C-terminal telopeptide of type Ⅰ collagen (ICTP) in breast cancer patients with bone metastases. METHODS: Serum and urine samples from 68 women with advanced breast cancer who received the treatment in Jilin Cancer Hospital between October 2012 and October 2008 were collected before and 2 months after treatment. Among them, 35 patients had bone metastases (group A), including 12 cases with single bone metastasis and 23 cases with multiple bone metastases. 33 out of the 68 patients had other organ metastases (group B). 30 healthy females were included as the control group (group C). The levels of urine NTX and serum ICTP were measured by ELISA. RESULTS: The levels of NTx and ICTP of group A were significantly higher than those of groups B and C [NTx: (7.17±1.11) nmol/L vs. (2.08±0.22) nmol/L and (2.09±0.24) nmol/L, respectively, (P<0.05); ICTP: (7.75±1.14) ng/ml vs. (2.15±0.34) ng/ml and (2.22±0.31) ng/ml, respectively, (P<0.05)], while no significant difference was found between the groups B and C. Compared with the patients with single bone metastasis, the patients with ≥2 bone metastases had significantly higher NTx and ICTP levels [NTx: (7.69±0.93) nmol/L vs. (6.16±0.62) nmol/L, P<0.05; ICTP: (8.21±1.00) ng/ml) vs. (6.88±0.81) ng/ml (P<0.05)]. At two months after treatment, 40.0%(14/35) of patients with bone metastasis had partial remission (PR), 42.9%(15/35) of patients had stable disease (SD), and 6 patients with progressive disease (PD). Both urinary NTx and serum ICTP of the patients with PR and SD were significantly decreased compared with those before treatment (P<0.05). 10 cases of patients (28.6%) with bone metastases had skeletal-related events (SREs) during the treatment, including one PR patient (1/14, 7.1%), 5 SD patients (5/15, 33.3%) and 4 PD patients (4/6, 66.7%). CONCLUSION: The combined detection of urinary NTx and serum ICTP is of important significance for early diagnosis and efficacy evaluation and to control skeletal-related adverse events in breast cancer patients with bone metastases.


Sujet(s)
Tumeurs osseuses , Tumeurs du sein , Marqueurs biologiques tumoraux , Collagène de type I , Femelle , Humains , Peptides
16.
Zhonghua Zhong Liu Za Zhi ; 38(3): 211-7, 2016 Mar 23.
Article de Chinois | MEDLINE | ID: mdl-26988828

RÉSUMÉ

OBJECTIVE: To analyze whether there are differences in the efficacy and clinical outcomes to first-line tyrosine kinase inhibitors (TKI) therapy in Chinese patients with metastatic non-small-cell lung cancer (NSCLC) harboring different subtypes of epidermal growth factor receptor (EGFR) mutations. METHODS: A retrospective analysis was made on the clinical data of stage ⅢB or Ⅳ NSCLC patients who were diagnosed by histology and received EGFR mutation test, in order to confirm if there is any difference between the therapeutic effects of TKIs as first-line therapy and the prognosis. RESULTS: A total of 165 patients harboring EGFR exon 19 deletion (19del, n=71), exon 21 L858R mutation (L858R, n=80) or uncommon sensitive mutation (n=14) were treated with EGFR-TKIs for first-line treatment. The comparison among different groups of common types of sensitive mutations revealed that the objective response rate (ORR) of group 19del and group L858R were 57.8% and 45.0%, respectively (P=0.113). The disease control rate (DCR) was 93.0% and 93.8%, respectively (P=0.158). However, the ORR and DCR of uncommon sensitive mutation were 35.7% and 78.6%, which were significantly lower than that of the group 19del (P=0.035) and group L858R (P=0.020). The median progression-free survival (PFS) of group 19del, group L858R and uncommon sensitive mutation were 14.0 months, 7.8 months and 5.1 months, respectively (P=0.001). The median PFS of the group 19del was significantly longer than that of the group L858R (P=0.009). The median overall survival (OS) of these three groups had significant difference (22.8, 15.2 and 10.0 months) (P=0.048). But those of group 19del and group L858R were similar (P=0.152). The multivariate analysis indicated that ECOG-PS (P=0.030), cigarette smoking (P=0.013) and EGFR mutation types (P=0.034) are independent prognostic factors of OS. CONCLUSIONS: For Chinese NSCLC patients with different types of sensitive mutation, there are differences between their efficacy and prognosis of EGFR-TKIs as first-line treatment. The PFS of group 19del is obviously longer than that of other types of sensitive mutations, but have no significant differences in OS. The PFS and OS of patients with common types of sensitive mutation are better than those with uncommon sensitive mutation.


Sujet(s)
Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Récepteurs ErbB/antagonistes et inhibiteurs , Tumeurs du poumon/traitement médicamenteux , Mutation , Inhibiteurs de protéines kinases/usage thérapeutique , Protein-tyrosine kinases/antagonistes et inhibiteurs , Antinéoplasiques , Asiatiques , Carcinome pulmonaire non à petites cellules/génétique , Carcinome pulmonaire non à petites cellules/secondaire , Chine , Survie sans rechute , Exons , Humains , Tumeurs du poumon/génétique , Tumeurs du poumon/anatomopathologie , Analyse multifactorielle , Pronostic , Études rétrospectives
17.
Clin Pharmacol Ther ; 98(4): 442-9, 2015 Oct.
Article de Anglais | MEDLINE | ID: mdl-26082272

RÉSUMÉ

Few studies evaluated the effects of pentoxifylline on hard endpoints in patients with predialysis stage 5 chronic kidney disease (CKD). Thus, we tried to explore the effects of pentoxifylline and its interaction with renin-angiotensin-aldosterone system (RAAS) blockade on the development of endstage renal disease (ESRD) and mortality. This nationwide cohort study retrospectively included patients who had a serum creatinine level of >6 mg/dL and received erythropoiesis-stimulating agents (ESAs) between 2000 and 2010. We analyzed 7,366 pentoxifylline users and 7,366 propensity score-matched nonusers. Using Cox proportional hazard models, pentoxifylline reduced the risks of ESRD and the composite renal outcome but not that of mortality. In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy. This study suggests pentoxifylline is efficacious in slowing progression to ESRD in patients with predialysis stage 5 CKD.


Sujet(s)
Antagonistes du récepteur de type 1 de l'angiotensine-II/usage thérapeutique , Inhibiteurs de l'enzyme de conversion de l'angiotensine/usage thérapeutique , Défaillance rénale chronique/prévention et contrôle , Pentoxifylline/usage thérapeutique , Dialyse rénale , Insuffisance rénale chronique/traitement médicamenteux , Système rénine-angiotensine/effets des médicaments et des substances chimiques , Agents urologiques/usage thérapeutique , Sujet âgé , Antagonistes du récepteur de type 1 de l'angiotensine-II/effets indésirables , Inhibiteurs de l'enzyme de conversion de l'angiotensine/effets indésirables , Marqueurs biologiques/sang , Loi du khi-deux , Créatinine/sang , Évolution de la maladie , Association de médicaments , Femelle , Humains , Défaillance rénale chronique/diagnostic , Défaillance rénale chronique/mortalité , Modèles logistiques , Mâle , Adulte d'âge moyen , Analyse multifactorielle , Pentoxifylline/effets indésirables , Score de propension , Modèles des risques proportionnels , Insuffisance rénale chronique/diagnostic , Insuffisance rénale chronique/mortalité , Insuffisance rénale chronique/physiopathologie , Études rétrospectives , Facteurs de risque , Facteurs temps , Résultat thérapeutique , Agents urologiques/effets indésirables
18.
Int Nurs Rev ; 61(3): 336-43, 2014 Sep.
Article de Anglais | MEDLINE | ID: mdl-24847741

RÉSUMÉ

AIM: This paper analyses and illustrates the application of Bandura's self-efficacy construct to an innovative self-management programme for patients with both type 2 diabetes and coronary heart disease. BACKGROUND: Using theory as a framework for any health intervention provides a solid and valid foundation for aspects of planning and delivering such an intervention; however, it is reported that many health behaviour intervention programmes are not based upon theory and are consequently limited in their applicability to different populations. The cardiac-diabetes self-management programme has been specifically developed for patients with dual conditions with the strategies for delivering the programme based upon Bandura's self-efficacy theory. This patient group is at greater risk of negative health outcomes than that with a single chronic condition and therefore requires appropriate intervention programmes with solid theoretical foundations that can address the complexity of care required. SOURCES OF EVIDENCE: The cardiac-diabetes self-management programme has been developed incorporating theory, evidence and practical strategies. DISCUSSION: This paper provides explicit knowledge of the theoretical basis and components of a cardiac-diabetes self-management programme. Such detail enhances the ability to replicate or adopt the intervention in similar or differing populations and/or cultural contexts as it provides in-depth understanding of each element within the intervention. CONCLUSION: Knowledge of the concepts alone is not sufficient to deliver a successful health programme. Supporting patients to master skills of self-care is essential in order for patients to successfully manage two complex, chronic illnesses. IMPLICATIONS FOR NURSING PRACTICE OR HEALTH POLICY: Valuable information has been provided to close the theory-practice gap for more consistent health outcomes, engaging with patients for promoting holistic care within organizational and cultural contexts.


Sujet(s)
Autosurveillance glycémique/méthodes , Maladie coronarienne/prévention et contrôle , Diabète de type 2/soins infirmiers , Cardiomyopathies diabétiques/prévention et contrôle , Promotion de la santé/organisation et administration , Modèles de soins infirmiers , Autosoins/méthodes , Maladie chronique , Comorbidité , Maladie coronarienne/épidémiologie , Diabète de type 2/épidémiologie , Cardiomyopathies diabétiques/épidémiologie , Humains , Mise au point de programmes , Auto-efficacité
19.
Leukemia ; 28(1): 34-43, 2014 Jan.
Article de Anglais | MEDLINE | ID: mdl-23979521

RÉSUMÉ

The ability of cancer to evolve and adapt is a principal challenge to therapy in general and to the paradigm of targeted therapy in particular. This ability is fueled by the co-existence of multiple, genetically heterogeneous subpopulations within the cancer cell population. Increasing evidence has supported the idea that these subpopulations are selected in a Darwinian fashion, by which the genetic landscape of the tumor is continuously reshaped. Massively parallel sequencing has enabled a recent surge in our ability to study this process, adding to previous efforts using cytogenetic methods and targeted sequencing. Altogether, these studies reveal the complex evolutionary trajectories occurring across individual hematological malignancies. They also suggest that while clonal evolution may contribute to resistance to therapy, treatment may also hasten the evolutionary process. New insights into this process challenge us to understand the impact of treatment on clonal evolution and inspire the development of novel prognostic and therapeutic strategies.


Sujet(s)
Évolution moléculaire , Tumeurs hématologiques/génétique , Tumeurs hématologiques/anatomopathologie , Tumeurs hématologiques/thérapie , Humains
20.
Clin Microbiol Infect ; 20(7): O428-34, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24237662

RÉSUMÉ

Aeromonas dhakensis, often phenotypically identified as Aeromonas hydrophila, is an important human pathogen. The present study aimed to compare the clinical and biological features of A. dhakensis and A. hydrophila isolates from human wounds. A total of 80 Aeromonas wound isolates collected between January 2004 and April 2011 were analysed. The species was identified by the DNA sequence matching of rpoD and gyrB (or rpoB if necessary). Most of the Aeromonas isolates were identified as A. dhakensis (37, 46.3%), and 13 (16.3%) as A. hydrophila. Both species alone can cause severe skin and soft-tissue infections. More A. dhakensis isolates were found in wounds exposed to environmental water (32.4% vs 0%, p 0.042). More biofilm formation was noted among A. dhakensis isolates (mean optical density at 570 nm, 1.23 ± 0.09 vs 0.78 ± 0.21, p 0.03). The MICs of ceftriaxone, imipenem and gentamicin for A. dhakensis isolates were higher (p <0.0001, <0.04, and <0.01, respectively). The survival rates of Caenorhabditis elegans co-incubated with A. dhakensis from day 1 to day 3 were lower than those of worms infected with A. hydrophila in liquid toxicity assays (all p values <0.01). Isolates of A. dhakensis exhibited more cytotoxicity, as measured by the released leucocyte lactate dehydrogenase levels in human normal skin fibroblast cell lines (29.6 ± 1.2% vs 20.6 ± 0.6%, p <0.0001). The cytotoxin gene ast was primarily present in A. hydrophila isolates (100% vs 2.7%, p <0.0001). In summary, A. dhakensis is the predominant species among Aeromonas wound isolates, and more virulent than A. hydrophila.


Sujet(s)
Aeromonas/classification , Aeromonas/isolement et purification , Infections bactériennes à Gram négatif/épidémiologie , Infections bactériennes à Gram négatif/microbiologie , Adulte , Aeromonas/pathogénicité , Aeromonas/physiologie , Sujet âgé , Animaux , Antibactériens/pharmacologie , Biofilms/croissance et développement , Caenorhabditis elegans/microbiologie , Caenorhabditis elegans/physiologie , Ceftriaxone/pharmacologie , Survie cellulaire , DNA gyrase/génétique , DNA-directed RNA polymerases/génétique , Femelle , Fibroblastes/microbiologie , Fibroblastes/physiologie , Gentamicine/pharmacologie , Humains , Imipénem/pharmacologie , Mâle , Tests de sensibilité microbienne , Adulte d'âge moyen , Données de séquences moléculaires , Prévalence , Analyse de séquence d'ADN , Infections des tissus mous/épidémiologie , Infections des tissus mous/microbiologie , Analyse de survie , Taïwan/épidémiologie , Infection de plaie/épidémiologie , Infection de plaie/microbiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...